An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
Highlands Ranch Hospital
University of Colorado Hospital
Principal Investigator
Antonio Jimeno, MD, PhD
Study ID
Protocol Number: 23-1812
More information available at ClinicalTrials.gov: NCT05814666
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers